✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Key takeaways
- GLP-1 receptor agonists (semaglutide, retatrutide research peptide) are the most effective pharmacological weight-loss agents available — 15-25% body-weight reduction at 12-18 months.
- Orlistat is the longest-running OTC-adjacent weight-loss drug — modest effect (~3-5 kg over 12 months) but real, with no systemic side-effect profile.
- SGLT-2 inhibitors add a 2-3 kg weight-loss effect alongside their primary cardiovascular and renal benefit in diabetic patients.
- Lifestyle remains foundational — pharmacotherapy multiplies the benefit of caloric restriction and physical activity, but doesn’t replace either.
- Below: 10 best weight-loss medications for 2026, organised by mechanism class with realistic outcome expectations.
Best Weight Loss Medications in 2026: 10 Effective Options From Orlistat to Retatrutide
Pharmacological weight management has been transformed in the last five years by GLP-1 receptor agonists. Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) deliver weight reductions previously only achievable with bariatric surgery. The market has rapidly evolved to include retatrutide and triple-receptor agonists in the research-peptide space.
This guide ranks the 10 best weight-loss medications available in 2026, with realistic expectations for each. The TL;DR: if you’re after maximum weight loss, GLP-1 RAs (or the research-peptide retatrutide) are dominant; orlistat remains a viable lower-cost option; SGLT-2 inhibitors add weight loss as a bonus to diabetes treatment.
Why the weight-loss treatment landscape changed
Until 2020, the most effective weight-loss medications produced 5-8% body-weight reductions over 12 months. Bariatric surgery was the only way to reliably achieve 20%+ reductions. Then GLP-1 receptor agonists arrived: STEP-1 (semaglutide 2.4 mg weekly) showed mean 14.9% body-weight reduction at 68 weeks. SURMOUNT-1 (tirzepatide 15 mg weekly) showed mean 22.5%. Retatrutide phase-2 data showed 24.2% at 48 weeks.
That’s the order-of-magnitude shift. The other classes (orlistat, SGLT-2, alpha-glucosidase inhibitors) remain useful — particularly for cost-constrained or contraindicated patients — but they sit in the 3-7% effect range, not 15-25%.
For the specific GLP-1 RA / GIP-RA / triple-agonist comparison, see our detailed Ozempic alternatives guide. This page covers the broader weight-loss medication landscape including non-GLP-1 options.
1. Retatrutide (Research Peptide, GLP-1 + GIP + Glucagon Triple Agonist)
Class: Triple agonist (research peptide) · View product
Retatrutide is the most potent weight-loss agent in current development — a triple agonist of GLP-1, GIP, and glucagon receptors. Phase-2 trial results (NEJM 2023) showed 24.2% mean body-weight reduction at 48 weeks at the highest dose. Phase 3 trials (TRIUMPH program) are ongoing. Available at MedsBase as a research peptide for laboratory study; not FDA-approved for clinical use.
Pick for: research applications, peptide-experienced users in the research community pursuing the highest-magnitude weight-loss agent currently available.
2. Orligal-120 (Orlistat 120 mg) — Most-Established Brand
Class: Lipase inhibitor · Manufacturer: Intas · View product
Orligal-120 is generic orlistat 120 mg — the prescription-strength dose (vs the 60 mg OTC version). Orlistat inhibits pancreatic and gastric lipases, blocking ~30% of dietary fat absorption. Modest but real effect: 3-5 kg additional weight loss over 12 months versus diet alone. It works best when paired with a moderate-fat (≤30% of calories) diet — not low-fat (no substrate to act on) or high-fat (overwhelming the inhibition + GI side effects).
Side effects: oily/loose stools, fecal urgency, occasional fecal incontinence — particularly with high-fat meals. Reduce fat content to control. Multivitamin (with fat-soluble A, D, E, K) recommended due to mild fat-soluble vitamin malabsorption.
Pick for: moderate weight-loss goals, GLP-1-RA-contraindicated patients, cost-conscious regimens.
3. Vyfat (Orlistat 120 mg) — Alternative Brand
Class: Lipase inhibitor · Manufacturer: Intas · View product
Vyfat is another generic orlistat 120 mg. Same active, same dose, same effect as Orligal-120 and other orlistat brands. Choice between brands is mostly preference and pricing.
Pick for: alternative orlistat brand, comparable to Orligal-120.
4. Slimtop (Orlistat 120 mg)
Class: Lipase inhibitor · Manufacturer: Healing Pharma · View product
Slimtop is Healing Pharma’s orlistat 120 mg. Same therapeutic profile as other orlistat brands. Often the most cost-effective option in the orlistat class.
Pick for: budget-tier orlistat, long-term cost-effective lipase inhibition.
5. Obelit (Orlistat 60/120 mg)
Class: Lipase inhibitor · Manufacturer: Intas · View product
Obelit is available in both 60 mg (OTC equivalent) and 120 mg (prescription strength) forms. The 60 mg dose has a milder side-effect profile but proportionally less weight-loss effect. Useful for patients trialling orlistat to gauge GI tolerability before committing to the 120 mg dose.
Pick for: orlistat first-time users, GI-side-effect-sensitive patients, gradual escalation.
6. Orlijohn (Orlistat 120 mg)
Class: Lipase inhibitor · Manufacturer: Johnlee Pharma · View product
Orlijohn is Johnlee’s orlistat 120 mg variant. Identical active to other orlistat brands. Often available at competitive pricing.
Pick for: alternative orlistat sourcing.
7. Jardiance (Empagliflozin 10/25 mg) — SGLT-2 Inhibitor
Class: SGLT-2 inhibitor · Manufacturer: Boehringer Ingelheim / Lilly · View product
SGLT-2 inhibitors cause urinary glucose excretion, leading to a calorie-loss mechanism (~200-300 kcal/day) that translates to 2-3 kg weight loss over 12 months. Primary indication is T2DM with cardiovascular or renal benefit, but the weight-loss effect is real and stable. Useful as a “weight loss + diabetes” two-fer for T2DM patients.
Pick for: T2DM patients prioritising weight loss; off-label weight-loss adjunct in non-diabetic patients (less evidence).
8. Forxiga (Dapagliflozin 5/10 mg) — SGLT-2 Inhibitor
Class: SGLT-2 inhibitor · Manufacturer: AstraZeneca · View product
Forxiga has nearly equivalent weight-loss effect to Jardiance. Choice between the two is mostly clinical preference based on outcome trial fit (DAPA-HF for heart failure, DAPA-CKD for kidney disease) and personal tolerability.
Pick for: alternative SGLT-2 weight-loss adjunct.
9. Lipaglyn (Saroglitazar 4 mg) — Dual PPAR Agonist
Class: Dual PPAR-α/γ agonist · Manufacturer: Zydus · View product
Lipaglyn (saroglitazar) is a dual PPAR-α/γ agonist primarily used for diabetic dyslipidaemia and NAFLD/NASH. Its weight effect is mild but real — 1-2 kg over 12 months — and crucially it improves liver histology in NAFLD/NASH, conditions that often co-exist with obesity. Available primarily in India and Mexico; not FDA-approved.
Pick for: obese patients with concurrent NAFLD/NASH and dyslipidaemia.
10. AyurSlim Capsule (Polyherbal Adjunct)
Class: Ayurvedic polyherbal supplement · Manufacturer: Himalaya · View product
AyurSlim contains Garcinia cambogia, gymnema, fenugreek, and other Ayurvedic herbs. Effect size is small (1-2 kg over 12 weeks in small clinical trials) and the evidence base is weaker than the pharmacological options above. Useful as a low-cost adjunct or for patients who specifically want a herbal/non-pharmaceutical option, but not a replacement for evidence-based therapy.
Pick for: mild weight-loss goals, herbal-preference patients, supplementary use alongside lifestyle changes.
Comparison table: 10 weight-loss medications at a glance
| Treatment | Class | Expected weight loss (12 mo) | Cost tier |
|---|---|---|---|
| Retatrutide | GLP-1+GIP+Glucagon (research) | 15-24% | Mid-high (research peptide) |
| Orligal-120 | Lipase inhibitor | 3-5 kg (~3-5%) | Low |
| Vyfat | Lipase inhibitor | 3-5 kg (~3-5%) | Low |
| Slimtop | Lipase inhibitor | 3-5 kg (~3-5%) | Low |
| Obelit (120 mg) | Lipase inhibitor | 3-5 kg (~3-5%) | Low |
| Orlijohn | Lipase inhibitor | 3-5 kg (~3-5%) | Low |
| Jardiance | SGLT-2 | 2-3 kg (~2-3%) | Mid |
| Forxiga | SGLT-2 | 2-3 kg (~2-3%) | Mid |
| Lipaglyn | Dual PPAR-α/γ | 1-2 kg (~1-2%) | Mid |
| AyurSlim | Polyherbal | 1-2 kg (~1-2%) | Low |
Decision shortcut
- Maximum weight loss, willing to use a research peptide: Retatrutide (research-peptide framing — laboratory use only, not clinical).
- Substantial weight loss, conventional clinical pharmacology: see our Ozempic alternatives guide for GLP-1 RA options including Rybelsus oral semaglutide.
- Moderate weight loss, low-cost, non-systemic: orlistat (Orligal-120, Vyfat, Slimtop) + diet adjustment.
- Diabetes + weight loss two-fer: Jardiance or Forxiga as add-on to metformin.
- Obesity + NAFLD/NASH: Lipaglyn for dual PPAR liver/lipid effect.
Frequently asked questions
What is the most effective weight-loss medication?
Currently, retatrutide research peptide produces the largest weight loss (~24% at 48 weeks in trial data). Among approved clinical agents, tirzepatide and semaglutide GLP-1 RAs lead at 15-22% body weight reduction. See our Ozempic alternatives guide for the GLP-1 / GIP / dual-agonist landscape in detail.
Is orlistat safe?
Yes, with caveats. Orlistat is non-systemic — it acts in the gut and is not significantly absorbed. Side effects are GI (oily stools, fecal urgency) and rare reports of severe liver injury. Take a multivitamin containing fat-soluble vitamins (A, D, E, K) due to mild malabsorption. Don’t use in malabsorption syndromes or cholestasis.
Will SGLT-2 inhibitors help me lose weight if I’m not diabetic?
Off-label evidence is limited but suggests modest weight loss (~2 kg) in non-diabetic obese patients. The agents are FDA-approved for T2DM and HF. For non-diabetic weight-loss applications, GLP-1 RAs are the better-evidenced choice — and approved for obesity (BMI ≥30 or BMI ≥27 with weight-related comorbidity).
Can I combine GLP-1 RAs with other weight-loss medications?
GLP-1 RAs + SGLT-2 inhibitors are commonly combined in T2DM patients with weight as a priority. GLP-1 RA + orlistat has not been formally studied; the combination isn’t theoretically problematic but expected GI side effects from each may be additive.
What’s the difference between Ozempic and Wegovy?
Both are semaglutide. Ozempic 0.5/1/2 mg is dosed weekly for T2DM. Wegovy 2.4 mg is dosed weekly for chronic weight management. Same molecule, different label and dose schedule. Rybelsus is the oral form (3/7/14 mg daily). See our Ozempic alternatives guide for the full landscape.
Is retatrutide approved for weight loss?
No — retatrutide is in phase-3 trials (TRIUMPH program) and is not yet FDA-approved for clinical use. MedsBase carries it as a research peptide for laboratory applications, not clinical weight-loss use.
How important is diet alongside medication?
Critical. All weight-loss medications work best when combined with caloric restriction (~500 kcal/day deficit), increased protein intake (1.2-1.6 g/kg/day to preserve lean mass), and physical activity. Pharmacotherapy multiplies the benefit of lifestyle changes; it doesn’t replace them.
What about diabetes medications for weight loss specifically?
Among diabetes-approved drugs, GLP-1 RAs (Rybelsus / Ozempic) deliver the most weight loss. SGLT-2 inhibitors (Jardiance / Forxiga / Invokana) deliver 2-3 kg. Metformin contributes 1-2 kg. Sulfonylureas, TZDs, and insulin cause weight gain. See our Best Diabetes Medications guide.
Bottom line
Pharmacological weight loss in 2026 has two tiers. Tier 1 (GLP-1 RAs / triple agonists / retatrutide research peptide) delivers 15-25% body-weight reductions and is the new standard for substantial weight loss. Tier 2 (orlistat, SGLT-2, dual PPAR) delivers 2-5 kg over 12 months — useful for moderate goals or as adjuncts. Pick by the magnitude of effect needed.
Related guides: Best Ozempic alternatives 2026 · Best diabetes medications 2026 · Tirzepatide vs semaglutide · All weight-loss products
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.